Compare HOVR & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ADVM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 94.6M |
| IPO Year | N/A | 2014 |
| Metric | HOVR | ADVM |
|---|---|---|
| Price | $1.67 | $4.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.50 | ★ $11.60 |
| AVG Volume (30 Days) | ★ 932.2K | 497.5K |
| Earning Date | 01-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,192.00 |
| Revenue Next Year | $55.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $1.78 |
| 52 Week High | $4.18 | $6.12 |
| Indicator | HOVR | ADVM |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 58.20 |
| Support Level | $1.71 | $4.15 |
| Resistance Level | $1.95 | $4.23 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 37.50 | 95.22 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.